Jan Pierre's presentation at DIA US 2010 Quality CT discussed effective monitoring and auditing in clinical trials, covering regulatory and industry perspectives on quality clinical trials; identifying key FDA Form 483 observations related to inadequate sponsor oversight and monitoring practicies; and describing precision monitoring and auditing strategies and tools for efficient and effective clinical trial process.